|
01 Apr 2018 |
Social |
Survey of 442 Dutch axial SpA patients finds Hidradenitis suppurativa twice as common (9.1% vs 4.1%) in AxSpA - HS/AxSpA more likely female with higher ASAS & BASDAI scores w/ more dactylitis & enthesitis. https://t.co/yJeyIr5uiM |
|
|
27 Mar 2018 |
Social |
Survey of 442 Dutch axial SpA patients finds Hidradenitis suppurativa twice as common (9.1% vs 4.1%) in AxSpA - HS/AxSpA more likely female with higher ASAS & BASDAI scores w/ more dactylitis & enthesitis. https://t.co/yJeyIr5uiM |
|
|
26 Mar 2018 |
Social |
RT @DrPetryna: FUTURE 5: secukinumab inhibits radiographic progression& improves enthesitis in #PsA : 24 wk vdH-mTSS secukinumab vs placebo… |
|
|
22 Mar 2018 |
Social |
FDA Approves Ilumya (tildrakizumab for Moderate-to-Severe Plaque Psoriasis. It binds p19 subunit of IL-23, inhibiting binding to IL-23 receptor. Given as 100 mg sc at Wk 0, 4 & q 12wks; 2nd IL-23 inhib approved for Pso. https://t.co/q9bQTVqN0t |
|
|
20 Mar 2018 |
Social |
Danish/Swedish study of 8097 births in 6103 psoriasis women & 964 births in 753 PsA women shows increased gestational DM, HTN, preeclampsia, cesarean delivery, pre-term birth & low birth weight in mothers; moreso with severe psoriasis https://t.co/DjrNqiRlgA |
|
|
14 Mar 2018 |
News |
Bone Marrow Edema Found in SI Joint of Athletes |
|
|
14 Mar 2018 |
Social |
ew-onset inflammatory back pain have just a 30% chance of developing spondyloarthritis during the next 10 years, and a 43% probability of back pain resolution, published in Arthritis and Rheumatology https://t.co/4CcUqtTYDV |
|
|
07 Mar 2018 |
Social |
Checkout #RWCS video by Dr. Eric Ruderman as he gives an update axial spondyloarthritis from the 2018 RWCS meeting in Maui. https://t.co/UUFApp9Pnn |
|
|
19 Feb 2018 |
Social |
2018 AAD presentations on upadacitinib (Abbvies JAK1 inhibitor) shows it effective in reducine pruritus, with rapid responses in psoriasis by Week. Also under study for atopic dermatitis and more. https://t.co/6c4yauVPCC |
|
|
13 Feb 2018 |
Social |
Research from the UK Clinical Practice Research Database shows among 6783 incident cases of Psoriatic arthritis,there was a significantly increased risk of developing uveitis (RR 3.55) & Crohn’s disease (RR 2.96), but not ulcerative colitis, https://t.co/8RJ0jMPR15 |
|
|
08 Feb 2018 |
News |
Recurrent Uveitis Increases the Risk of Ankylosing Spondylitis |
|
|
05 Feb 2018 |
Social |
Opioids in Ankylosing spondylitis tend to be used for more subjective measures and not for objective inflammatory dz; also more likely to be using anxiolytic, hypnotic, antidepressant, and muscle relaxant medications. https://t.co/FcNpEzSZeZ |
|
|
01 Feb 2018 |
News |
Opioid Use in Ankylosing Spondylitis |
|
|
31 Jan 2018 |
Social |
Checkout Cush and the RheumNow Panel #ACR17 video discussing highlights from ACR 2017 in San Diego. https://t.co/OI3BYocnsy |
|
|
28 Jan 2018 |
Social |
RAPID AxSpA study shows certolizumab Rx had 81% of AS without Xray progress) after 4 years (same 79% as secukinumab MEASURE 1 study). https://t.co/twW0PdmsDJ |
|
|
23 Jan 2018 |
News |
Cimzia Limits Xray Progression in Axial Spondyloarthritis |
|
|
22 Jan 2018 |
News |
Apremilast’s Rapid Onset in Psoriatic Arthritis |
|
|
22 Jan 2018 |
Social |
Price of 6 mos of Psoriasis Rx: Guselkumab $29k; Taltz $28.6k; Humira $26.6k; $Enbrel 26.6k; Cosentyx $26.5k; Stelara $19k; Remicade $14k; Inflectra $11.3k; Renflexix $9k https://t.co/JoDA01agbz |
|
|
18 Jan 2018 |
Social |
RT @ARD_BMJ: Evaluation of #efficacy of #apremilast in a phaseIIIb #RCT outlined fast response after week 2, with continuing efficacy over… |
|
|
16 Jan 2018 |
News |
Salt Drives Gut-Brain Connection via IL-17 |
|
